临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
AZD8055
中文名称:[5-[2,4-二((3S)-3-甲基吗啉-4-基)吡啶并[2,3-d]嘧啶-7-基]-2-甲氧基苯基]甲醇
CAS号:1009298-09-2
分子式: C25H31N5O4 分子量: 465.54
产品形式: free base
研发状态: Completed
研发用途: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Malignant Glioma; Brainstem Glioma
研究机构: National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC)
研发日期: March 4 2011
研发阶段: Phase 1
AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.
Daclatasvir (BMS-790052)
中文名称:达卡他韦
CAS号:1009119-64-5
分子式: C40H50N8O6 分子量: 738.88
产品形式: free base
研发状态: Recruiting
研发用途: HCV Infection
研究机构: ANRS Emerging Infectious Diseases
研发日期: August 7 2023
研发阶段: Not Applicable
Daclatasvir (BMS-790052, EBP883) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.
CH5132799
中文名称:[5-[7-甲磺酰基-2-(吗啉-4-基)-6,7-二氢-5H-吡咯并[2,3-D]嘧啶-4-基]嘧啶-2-基]胺
CAS号:1007207-67-1
分子式: C15H19N7O3S 分子量: 377.42
产品形式: free base
研发状态: Completed
研发用途: Solid Tumors
研究机构: Chugai Pharma Europe Ltd.
研发日期: Aug-10
研发阶段: Phase 1
CH5132799 (MEN1611, PA799) inhibits class I PI3Ks, particularly PI3Kα with IC50 of 14 nM; less potent to PI3Kβδγ, while sensitive in PIK3CA mutations cell lines. Phase 1.
Desloratadine
中文名称:地氯雷他定
CAS号:100643-71-8
分子式: C19H19ClN2 分子量: 310.82
产品形式: free base
研发状态: Not yet recruiting
研发用途: Allergic Rhinitis
研究机构: EMS
研发日期: February 15 2025
研发阶段: Phase 3
Desloratadine (SCH-34117, NSC 675447) is a potent antagonist for human histamine H1 receptor with IC50 of 51 nM.
Tirasemtiv (CK-2017357)
中文名称:Tirasemtiv(CK-2017357)抑制剂
CAS号:1005491-05-3
分子式: C12H14N4O 分子量: 230.27
产品形式: Free Base
研发状态: Completed
研发用途: Amyotrophic Lateral Sclerosis
研究机构: Cytokinetics
研发日期: Nov-11
研发阶段: Phase 2
Tirasemtiv (CK-2017357, CK-357) is a direct fast skeletal muscle troponin activator that sensitizes the sarcomere to calcium.
LCL161
中文名称:LCL161,凋亡蛋白抑制因子抑制剂
CAS号:1005342-46-0
分子式: C26H33FN4O3S 分子量: 500.63
产品形式: free base
研发状态: Completed
研发用途: Multiple Myeloma
研究机构: Novartis Pharmaceuticals; Novartis
研发日期: December 18 2017
研发阶段: Phase 1
LCL-161, a small molecule second mitochondrial activator of caspase (SMAC) mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
